Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/151618
Full metadata record
DC FieldValueLanguage
dc.creatorAraújo, N
dc.creatorCosta, A
dc.creatorLopes-Conceição, L
dc.creatorFerreira, A
dc.creatorCarneiro, F
dc.creatorOliveira, J
dc.creatorBraga, I
dc.creatorMorais, S
dc.creatorPacheco-Figueiredo, L
dc.creatorRuano, L
dc.creatorCruz, VT
dc.creatorPereira, S
dc.creatorLunet, N
dc.date.accessioned2023-08-02T09:08:02Z-
dc.date.available2023-08-02T09:08:02Z-
dc.date.issued2022
dc.identifier.issn2059-7029
dc.identifier.urihttps://hdl.handle.net/10216/151618-
dc.description.abstractBackground: Androgen-deprivation therapy (ADT) has been associated with cognitive decline, but results are conflicting. This study describes changes in cognitive performance in patients with prostate cancer, according to ADT, during the first year after prostate cancer diagnosis. Patients and methods: Patients with prostate cancer treated at the Portuguese Institute of Oncology of Porto (n = 366) were evaluated with the Montreal Cognitive Assessment (MoCA), before treatment and after 1 year. All baseline evaluations were performed before the coronavirus disease 2019 (COVID-19) pandemic and 69.7% of the 1-year assessments were completed after the first lockdown. Cognitive decline was defined as the decrease in MoCA from baseline to the 1-year evaluation below 1.5 standard deviations of the distribution of changes in the whole cohort. Participants scoring below age- and education-specific normative reference values in the MoCA were considered to have cognitive impairment. Age- and education-adjusted odds ratios (aORs) were computed for the association between ADT and cognitive outcomes. Results: Mean MoCA scores increased from baseline to the 1-year evaluation (22.3 versus 22.8, P < 0.001). Cognitive decline was more frequent in the ADT group, and even more after the onset of the COVID-19 pandemic (aOR 6.81 versus 1.93, P for interaction = 0.233). The 1-year cumulative incidence of cognitive impairment was 6.9% (9.1% before and 3.7% after the pandemic onset), which was higher among patients receiving ADT, but only after the pandemic (aOR 5.53 versus 0.49, P for interaction = 0.044). Conclusions: ADT was associated with worse cognitive performance of patients with prostate cancer, mostly among those evaluated after the first COVID-19 lockdown. © 2022 The Authors
dc.description.sponsorshipFunding text 1: This study was funded by the European Regional Development Fund through the Operational Programme Competitiveness and Internationalisation, and national funding from the Fundação para a Ciência e a Tecnologia - FCT (Portuguese Ministry of Science, Technology and Higher Education) under the project ‘NEON-PC - Neuro-oncological complications of prostate cancer: longitudinal study of cognitive decline’ (POCI-01-0145-FEDER-032358; Ref. PTDC/SAU-EPI/32358/2017), and the Unidade de Investigação em Epidemiologia - Instituto de Saúde Pública da Universidade do Porto (EPIUnit; UIDB/04750/2020) and Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (LA/P/0064/2020), financed by national funds from FCT . AC and SM were funded under the scope of the project ‘NEON-PC - Neuro-oncological complications of prostate cancer: longitudinal study of cognitive decline’ (POCI-01-0145-FEDER-032358; Ref. PTDC/SAU-EPI/32358/2017). An individual PhD grant attributed to NA (SFRH/BD/119390/2016) was funded by FCT and the ‘ Programa Operacional Capital Humano ’ (POCH/FSE). ; Funding text 2: This study was funded by the European Regional Development Fund through the Operational Programme Competitiveness and Internationalisation, and national funding from the Fundação para a Ciência e a Tecnologia - FCT (Portuguese Ministry of Science, Technology and Higher Education) under the project ‘NEON-PC - Neuro-oncological complications of prostate cancer: longitudinal study of cognitive decline’ (POCI-01-0145-FEDER-032358; Ref. PTDC/SAU-EPI/32358/2017), and the Unidade de Investigação em Epidemiologia - Instituto de Saúde Pública da Universidade do Porto (EPIUnit; UIDB/04750/2020) and Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (LA/P/0064/2020), financed by national funds from FCT. AC and SM were funded under the scope of the project ‘NEON-PC - Neuro-oncological complications of prostate cancer: longitudinal study of cognitive decline’ (POCI-01-0145-FEDER-032358; Ref. PTDC/SAU-EPI/32358/2017). An individual PhD grant attributed to NA (SFRH/BD/119390/2016) was funded by FCT and the ‘Programa Operacional Capital Humano’ (POCH/FSE). The authors have no relevant financial or nonfinancial interests to disclose. The datasets generated and analysed in this study will not be publicly available given that the included patients do not specifically provide their consent for public sharing of their data and that anonymization is unlikely to be feasible, because the identification of patients treated in only one institution within a relatively short period may be possible when taking sociodemographic and clinical characteristics into account. Ethics approval was obtained from the Ethics Committee of the Portuguese Institute of Oncology of Porto (Ref. CES 89/017) and by the Portuguese Data Protection Authority (Authorisation 3478/2017). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants after the project's aims and procedures had been fully explained by a member of the research team. Not applicable.
dc.language.isoeng
dc.publisherElsevier
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/SAU-EPI/32358/2017/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04750/2020/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/SAU-EPI/32358/2017/PT
dc.relation.ispartofESMO Open. 2022 Apr;7(2):100448. doi: 10.1016/j.esmoop.2022.100448. Epub 2022 Mar 7.
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCOVID-19, complications; hormone antagonists/analogues and derivatives; hormone substitutes; hormones; longitudinal studies; neurocognitive disorders; prostate cancer
dc.titleAndrogen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Saúde Pública da Universidade do Porto
dc.identifier.doi10.1016/j.esmoop.2022.100448
dc.relation.publisherversionhttps://www.esmoopen.com/article/S2059-7029(22)00064-3/fulltext
Appears in Collections:ISPUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
araujo-esmoo-2022.pdf390.42 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons